AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03293238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint line ultrasound
Description: Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
Study NCT03293238 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Joint line landmark
Description: Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
Study NCT03293238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapatellar ultrasound guided
Description: Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
Study NCT03293238 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Suprapatellar Landmark
Description: Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
Study NCT00058526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic SB719125 (Primary)
Description: Intramuscular injection
Study NCT01059253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AdvanStep training program - Turtle Pop
Description: Balance / mobility exercise program using the AdvanStep in a virtual reality context
Study NCT02011620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide-5-mononitrate
Description: Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
Study NCT06524557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: with chronic liver disease
Description: patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease
Study NCT00810485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: oral administration
Study NCT02507869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive affective response
Description: Participants adjust the intensity of their exercise to maintain a pleasant affective response.
Study NCT02507869 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity heart rate
Description: Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
Study NCT03709849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo
Description: the same as group description including dosage, frequency and duration
Study NCT03709849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo
Description: the same as group description including dosage, frequency and duration
Study NCT03709849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
Description: the same as group description including dosage, frequency and duration
Study NCT03709849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
Description: the same as group description including dosage, frequency and duration
Study NCT05162339 — intervention group
Intervention type: OTHER
Intervention: No intervention was made
Description: No intervention was made
Study NCT02873533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: geriatric care and longitudinal follow up
Description: geriatric care and longitudinal follow up
Study NCT02280031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid
Description: Capsule containing Acetylsalicylic Acid 80mg pill with lactose
Study NCT02280031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing placebo pill with lactose
Study NCT01397006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
Study NCT01397006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
Study NCT04236700 — intervention group
Intervention type: OTHER
Intervention: Oral clinical exam
Description: Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
Study NCT02875782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation and DM specific component intervention
Description: A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
Study NCT02875782 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: A simple, brief advice and a self-help general leaflet on smoking cessation
Study NCT01137916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 800 mg
Study NCT00434876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
Study NCT00434876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Inactive or inert pill which will be used as a comparator.
Study NCT02717819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Daily intake of supplement
Study NCT02717819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of supplement
Study NCT02717819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
Study NCT02717819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
Study NCT02717819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
Study NCT02717819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
Study NCT03530631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall
Description: Participants will be administered Adderall
Study NCT03530631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo
Study NCT03530631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered placebo
Study NCT00880074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo fluorine F-18 fluorothymidine PET
Study NCT00880074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT00880074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo fluorine F-18 fluorothymidine PET
Study NCT01042184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential therapy for 14 days
Description: D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
Study NCT01042184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential therapy for 10 days
Description: D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
Study NCT00613938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol (CG5503)
Description: 75mg capsule q4-6 hrs for 3 days
Study NCT01042184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple therapy for 14 days
Description: D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
Study NCT00613938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: 10mg capsule q4-6 hrs for 3 days
Study NCT02888821 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CLS-FUERTE
Description: The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
Study NCT01633372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Study NCT00810485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADX10059 Matching Placebo
Description: oral administration
Study NCT02888821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLS-FUERTE
Description: The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
Study NCT00800176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 12 weeks
Study NCT00800176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 2.5mg po daily for 12 weeks
Study NCT00800176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 5mg po daily for 12 weeks
Study NCT00800176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 10mg po daily for 12 weeks
Study NCT00800176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 20mg po daily for 12 weeks
Study NCT00800176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 40mg po daily for 12 weeks
Study NCT04830904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: personalized Lycra garments
Description: the subjects wear lycra garments during the assessment time and for some days after the assessment
Study NCT00879593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PtcCO2
Description: Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
Study NCT03887260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PCA pump
Description: Morphine given postoperatively.
Study NCT01586286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
Study NCT01586286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment Base
Description: Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
Study NCT00613938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule q4-6 hrs for 3 days
Study NCT03218033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Media
Study NCT03134989 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cochlear implant
Description: Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
Study NCT04813094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based integrated-management Program
Description: The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Everyone have their own area to ensure the privacy of participants. The research nurse has sent messages every day to care about the participant's condition. In this area, when the participant have an emergency, it not only provided textual information, but also provided telephone coaching.
Study NCT04813094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
Study NCT02177045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonovue, Bracco
Description: Intravenous injection
Study NCT03486132 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: repair of episiotomy
Description: Different techniques for repair of episiotomy incsicion
Study NCT02444689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Media Application
Description: Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
Study NCT02444689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care education
Study NCT00640900 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
Study NCT03887260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA pump
Description: Morphine given postoperatively.
Study NCT03887260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: Regional anaesthesia technique performed under ultrasound guidance before surgery
Study NCT03887260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
Study NCT03887260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
Study NCT00765882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide 290 micrograms
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study NCT00765882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide 145 micrograms
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study NCT00765882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study NCT01887821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study NCT01887821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin/Piperaquine
Study NCT02727556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual images
Study NCT04246333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mode of Delivery of Feeds
Description: Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
Study NCT02261129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan film-coated tablet
Study NCT02261129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan uncoated tablet
Study NCT02919280 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: The Dallas 2K is a 10-year natural history, longitudinal, prospective study of a cohort of 2,000 participants. There is no medication or non-medication treatment or intervention provided by this study.
Study NCT02943356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Patients will be treated with Tadalafil for 8 weeks
Study NCT03428438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation at home via SMS
Description: Cardiac rehabilitation
Study NCT01217099 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: methylprednisolone
Description: treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
Study NCT01217099 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: azithromycin
Description: control patients were iv azithromycin for 5 days.
Study NCT03951259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM934
Description: In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
Study NCT00640900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Description: Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
Study NCT01691937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Paravertebral block with ropivacaine
Description: Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
Study NCT01691937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with sufentanil
Description: Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
Study NCT01691937 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Patient-controlled analgesia with sufentanil
Description: Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
Study NCT01691937 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Paravertebral Block with Saline
Description: Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
Study NCT00962416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus eluted from an erodable stent coating (Biomatrix)
Description: The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.